Clinical Trial Update: Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 [Phase 3]

View source ↗

Summary

A Phase 3 extension study reports on long-term safety and efficacy of NNC-0156-0000-0009 in patients with Haemophilia B, supplementing NN7999-3747 and NN7999-37…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorders
• Haemophilia

Drugs mentioned

• NNC-0156-0000-0009

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2018-05-09